Proteins and Peptides

21 Oct 2019 OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency
17 Oct 2019 Horizon Therapeutics plc Initiates PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection) to Improve Management of Uncontrolled Gout for Adults with a Kidney Transplant
16 Oct 2019 Lilly Announces Phase 3 Study in Patients with Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint of Overall Survival
16 Oct 2019 Nektar Therapeutics Announces Initiation of First-in-Human Phase 1 Clinical Study of NKTR-255, an IL-15 Agonist, in Adults with Relapsed or Refractory Non-Hodgkin Lymphoma or Multiple Myeloma
16 Oct 2019 Aro Biotherapeutics Debuts Lead Centyrin Candidate at 2019 OTS Meeting
15 Oct 2019 AzurRx BioPharma Announces First Patients Dosed in Clinical Study for MS1819-SD in combination with PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
14 Oct 2019 DiaMedica Therapeutics Announces Clearance to Initiate Phase II Clinical Trial of DM199 for Chronic Kidney Disease
12 Oct 2019 Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration
10 Oct 2019 Galderma Announces Positive Phase 2 Results for its Proprietary Liquid Formulation of an Investigational Botulinum Toxin and Approval of New State-of-the-Art Manufacturing Facility
08 Oct 2019 FDA approves first treatment to increase pain-free light exposure in patients with a rare disorder
08 Oct 2019 FDA Approves Octapharma’s WILATE® for Hemophilia A in Adult and Adolescent Patients
08 Oct 2019 Pfenex Receives U.S. FDA Approval for PF708 to Treat Osteoporosis
08 Oct 2019 Intarcia Therapeutics Provides Regulatory Update - FDA Accepts Resubmitted New Drug Application For ITCA 650
08 Oct 2019 Stealth BioTherapeutics Presents Data on SBT-272 in Neurodegeneration
08 Oct 2019 Nektar Therapeutics Announces Initiation of Two Clinical Studies of Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients with Psoriasis and Atopic Dermatitis
08 Oct 2019 Axcella Provides Progress Updates for Liver Program Candidates AXA1125 and AXA1957
03 Oct 2019 Molecular Partners Announces First Patient Dosed in Phase 1 Trial of MP0310, a Novel Tumor-Localized Immunotherapy
02 Oct 2019 Ra Pharmaceuticals Announces Dosing of First Patient in Global Phase 3 Pivotal Study of Zilucoplan for gMG
02 Oct 2019 Evolus Receives Approval for Nuceiva™ in the European Union
01 Oct 2019 TYME Presents Supporting Data at ESMO 2019 from TYME-88-Panc Phase II Study Demonstrating Overall Survival Trends, Well Tolerated Safety, and Quality of Life Data in Patients with Advanced Pancreatic Cancer
01 Oct 2019 Cue Biopharma Initiates Patient Dosing in Phase 1 Study of CUE-101 for HPV16-driven Head and Neck Squamous Cell Carcinoma
29 Sep 2019 Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in China for Malignant Ascites
29 Sep 2019 Bicycle Therapeutics Announces Presentation of Updated Data from Phase I/IIa Trial Evaluating BT1718 in Patients with Advanced Solid Tumors at ESMO 2019 Annual Congress
27 Sep 2019 89bio Announces Dosing of First Patients in NASH Study and Issuance of Composition of Matter Patent
27 Sep 2019 Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Triple-Negative Breast Cancer Patients at the 2019 CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top